Switch theme
Sign up to access all valuation multiples
Alzchem Group AG is an international chemical company. The reportable segments of the company are Specialty Chemicals, Basics and Intermediates, and Other Holdings. The specialty chemicals segment focuses on the production and distribution of high-quality growth products, and the basics and intermediates segment covers the production of basic and intermediate products. It generates a majority of its revenue from the Specialty Chemical segment. Geographically it serves Europe, Asia, and the Rest of the world whilst deriving substantial revenue from Germany.
1908
1.7K+
LTM Revenue $634M
LTM EBITDA $122M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alzchem Group has a last 12-month revenue (LTM) of $634M and a last 12-month EBITDA of $122M.
In the most recent fiscal year, Alzchem Group achieved revenue of $623M and an EBITDA of $121M.
Alzchem Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alzchem Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $634M | XXX | $623M | XXX | XXX | XXX |
| Gross Profit | $407M | XXX | $405M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $122M | XXX | $121M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $91.9M | XXX | $87.8M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $63.4M | XXX | $60.7M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alzchem Group's stock price is EUR 123 (or $138).
Alzchem Group has current market cap of EUR 1.3B (or $1.4B), and EV of EUR 1.2B (or $1.4B).
See Alzchem Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.4B | XXX | XXX | XXX | XXX | $6.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alzchem Group has market cap of $1.4B and EV of $1.4B.
Alzchem Group's trades at 2.2x EV/Revenue multiple, and 11.5x EV/EBITDA.
Equity research analysts estimate Alzchem Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alzchem Group has a P/E ratio of 22.1x.
See valuation multiples for Alzchem Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 11.5x | XXX | XXX | XXX |
| EV/EBIT | 15.2x | XXX | 15.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.1x | XXX | 23.1x | XXX | XXX | XXX |
| EV/FCF | 23.5x | XXX | 11.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlzchem Group's last 12 month revenue growth is 6%
Alzchem Group's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Alzchem Group's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alzchem Group's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alzchem Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alzchem Group acquired XXX companies to date.
Last acquisition by Alzchem Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Alzchem Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alzchem Group founded? | Alzchem Group was founded in 1908. |
| Where is Alzchem Group headquartered? | Alzchem Group is headquartered in Germany. |
| How many employees does Alzchem Group have? | As of today, Alzchem Group has 1.7K+ employees. |
| Is Alzchem Group publicy listed? | Yes, Alzchem Group is a public company listed on FRA. |
| What is the stock symbol of Alzchem Group? | Alzchem Group trades under ACT ticker. |
| When did Alzchem Group go public? | Alzchem Group went public in 1999. |
| Who are competitors of Alzchem Group? | Similar companies to Alzchem Group include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of Alzchem Group? | Alzchem Group's current market cap is $1.4B |
| What is the current revenue of Alzchem Group? | Alzchem Group's last 12 months revenue is $634M. |
| What is the current revenue growth of Alzchem Group? | Alzchem Group revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Alzchem Group? | Current revenue multiple of Alzchem Group is 2.2x. |
| Is Alzchem Group profitable? | Yes, Alzchem Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alzchem Group? | Alzchem Group's last 12 months EBITDA is $122M. |
| What is Alzchem Group's EBITDA margin? | Alzchem Group's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Alzchem Group? | Current EBITDA multiple of Alzchem Group is 11.4x. |
| What is the current FCF of Alzchem Group? | Alzchem Group's last 12 months FCF is $59.3M. |
| What is Alzchem Group's FCF margin? | Alzchem Group's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Alzchem Group? | Current FCF multiple of Alzchem Group is 23.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
